Embraer S.A. Common Stock (EMBJ)

Total Liabilities

R$48.62B

Quarterly · Period ending: · BRL

EMBJ logo

EMBJ Total Liabilities

Latest reportedR$48.62B BRL
EMBJ Quarterly Total Liabilities · BRL (R$2.78B → R$48.62B)
High-resolution chart · PNG

EMBJ total liabilities history

Quarterly · BRL. Dates are reporting period ends; fiscal years can differ from calendar years.

Embraer S.A. Common Stock Total Liabilities — Quarterly (BRL)
Period endingTotal Liabilities (BRL)
48,618,254,000
47,917,810,000
49,885,611,000
45,810,647,000
46,372,565,000
48,058,775,000
52,438,465,000
45,109,145,000
43,354,774,000
39,079,134,000
38,059,045,000
38,069,854,000
38,348,363,000
39,215,514,000
39,148,157,000
38,668,377,000
35,966,948,436
33,488,409,075
41,389,697,000
41,086,739,000
37,485,390,000
42,816,319,000
39,558,874,050
44,789,340,000
39,377,646,749
39,878,250,974
26,625,199,538
29,784,486,486
28,245,864,243
28,293,530,080
28,491,774,000
31,329,658,000
30,197,272,000
25,866,528,000
25,788,685,000
24,899,967,000
26,237,874,000
25,825,205,000
25,171,813,000
27,272,613,000
26,057,460,000
27,957,808,000
30,558,240,000
29,949,133,000
23,508,456,000
20,511,380,000
16,372,700,820
16,245,791,000
14,262,732,000
14,730,405,871
15,251,301,000
15,014,493,000
14,422,939,631
13,665,307,721
6,130,600,000
12,564,761,000
6,375,400,000
6,290,500,000
10,501,000,975
6,002,700,000
5,995,000,000
5,562,500,000
5,259,500,000
9,572,217,200
9,886,209,600
10,337,729,000
6,006,500,000
6,175,200,000
6,064,352,000
6,075,018,000
6,364,600,000
12,501,758,000
6,175,536,000
5,963,000,000
5,747,705,000
6,074,803,000
11,817,745,000
5,185,636,000
11,157,297,101
12,291,295,000
5,503,863,000
5,162,093,000
12,103,498,000
5,470,752,000
12,026,703,000
12,039,585,000
12,561,453,000
14,634,641,000
15,786,577,000
13,621,404,000
15,079,986,000
12,299,646,000
11,302,566,000
8,450,806,000
8,140,383,543
8,450,515,000
6,560,342,734
5,876,902,000
4,920,183,123
6,067,997,317
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.